NCT07120347Recruiting
Remote Sensing for ADRD-Specific Activities Identification in Older Adults
Source: ClinicalTrials.gov · Last updated 13 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators aim to use smart-home sensors and artificial intelligence (AI) to monitor and detect Alzheimer's Disease and Related Dementias (ADRD)-specific daily activities among older adults, with the goal of early symptom detection and personalized support. Dementia, which impacts memory and cognition, remains a global concern. In the United States, more than 6.7 million individuals aged 65 and older are living with ADRD, and projected annual healthcare costs are expected to reach $1 trillion by 2050. This underscores the need for deeper understanding and innovative support. To address the unique challenges associated with ADRD, such as cognitive decline, personalized strategies that promote independent well-being are essential. Smart-home sensors can support older adults with ADRD as they continue to live in their homes. These sensors provide real-time data on health and daily activities, offering insights into their daily lives. However, adoption of these technologies is low, and the practical application of AI remains limited. This highlights the need for further research to make these devices more accessible to this population. The investigators' aims include: Conducting focus groups with individuals with and without ADRD and their caregivers to identify daily activities that can be measured using in-home sensors; Collecting in-home sensor data from older adults with and without ADRD; and Using AI to develop a tool for recognizing daily activities. The integration of smart-home sensors with advanced data-analysis techniques holds significant potential for transforming the support and care provided to individuals with ADRD. Ultimately, the investigators' findings will contribute to improving the quality of life for affected individuals and alleviating the burden on caregivers and healthcare systems.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 22 May 2025
- Start date
- 1 Aug 2024
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- University of Missouri-Columbia
- Diseases
- Alzheimer disease
- NCT number
- NCT07120347
What you commit to
- Study type: Interventional
- Planned participants: 16
- From 1 Aug 2024 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Clinical Dementia Rating (CDR) global score \> 1 (moderate or severe dementia)
Other
- Cognitive or functional impairments that would preclude meaningful participation in daily activities
Who the study is looking for
- Community-dwelling, English-speaking adults aged ≥ 50 years
- Clinical diagnosis of mild cognitive impairment or mild dementia (ADRD)
- Diagnosis established by a neuropsychologist, neurologist, or geriatrician within the University of Missouri Healthcare System
- Diagnosis confirmed using the latest consensus criteria and verified through record review
- No restriction on the etiology of the cognitive disorder (e.g., Alzheimer's disease, vascular dementia, mixed dementia)
Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Missouri Coordinator of this site? Confirm its status | Columbia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.